Effects of the angiotensin II receptor antagonist candesartan cilexetil on blood pressure and proteinuria in patients with autosomal dominant polycystic kidney disease [24]

Nephron

Volumn 86, Issue 3, 2000, Pages 385-386

  Nakamura, Tsukasa ^a   Ushiyama, Chifuyu ^a   Shimada, Noriaki ^b   Sekizuka, Keiko ^b   Ebihara, Isao ^b   Koide, Hikaru ^b  

^a Misato Junshin Hospital   (Japan)

^b KOTO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL;

ADULT; ALBUMIN BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY POLYCYSTIC DISEASE; LETTER; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; TREATMENT OUTCOME;

ADULT; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROTEINURIA; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0033674104     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (15)

1. Dietary soy protein effects on inherited polycystic kidney disease are influenced by gender and protein level
2. Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan
3. Polycystic kidney disease
4. Characteristics of very early-onset autosomal dominant polycystic kidney disease
5. Tubulocystic epithelium
6. Genesis and significance of hypertension in autosomal dominant polycystic kidney disease
7. Causes of death in autosomal dominant polycystic kidney disease
8. Hypertension, lipid abnormalities and cardiovascular changes in autosomal dominant polycystic kidney disease
9. Influence of the ACE gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease
10. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease
11. Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in Han: SPRD rats
12. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
13. The etiology, pathogenesis, and treatment of autosomal dominant polycystic kidney disease: Recent advances
14. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan
15. Effect of candesartan cilexetil in rats with chronic renal failure